LICENSE AGREEMENT between OPTINOSE AS and AVANIR PHARMACEUTICALS, INC.License Agreement • December 11th, 2013 • Avanir Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This LICENSE AGREEMENT (the “Agreement”) is entered into on July 1, 2013 (the “Effective Date”) between OptiNose AS, a Norwegian corporation, company registration number 982483131, with its principal place of business at Austliveien 1, 0751 Oslo, Norway, and its postal address at Pb 288 Roa, 0702 Oslo, Norway (“OptiNose”), and Avanir Pharmaceuticals, Inc., a Delaware corporation, with offices at 20 Enterprise, Suite 200, Aliso Viejo, CA 92656, U.S.A. (“Avanir”). OptiNose and Avanir are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO SUMMIT OFFICE LEASESummit Office Lease • December 11th, 2013 • Avanir Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO SUMMIT OFFICE LEASE (this “Amendment”) is made and entered into as of September 27, 2013, by and between ALISO VIEJO RP-V1, LLC, a Delaware limited liability company (“Landlord”), and AVANIR PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SUBLEASE AGREEMENTSublease Agreement • December 11th, 2013 • Avanir Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS SUBLEASE AGREEMENT (this “Sublease”) dated as of November 8, 2013 (the “Effective Date”), is made by and between VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a British Columbia corporation (“Sublandlord”), and AVANIR PHARMACEUTICALS, INC., a Delaware corporation (“Subtenant”).
